Table 3.
ICEMR/region | Drug efficacy trials | Ex vivo drug sensitivity | Drug resistance polymorphisms | ||
---|---|---|---|---|---|
ACT | CQ/primaquine | pvmdr1 | pvdhfr | ||
Southeast Asia | No | Yes | Yes | Yes | No |
South Asia | Yes | Yes | Yes | Yes | Yes |
PNG | AL, DP, ART/NQ, ART-SP | CQ-SP and AQ-SP, no primaquine | No | Yes | Yes |
ACT = artemisinin-based combination therapy; AL = artemether/lumefantrine; ART = artemisinin; AQ = amodiaquine; CQ = chloroquine; DP = dihydroartemisinin/piperaquine; ICEMR = the International Centers of Excellence for Malaria Research; MQ = mefloquine; NQ = naphthoquine; PNG = Papua New Guinea; SP = sulfadoxine/pyrimethamine.